Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Feb, 2016 | Pages:
109 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Myasthenia Gravis - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Myasthenia Gravis - Pipeline Review, H1 2016', provides an overview of the Myasthenia Gravis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Myasthenia Gravis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Myasthenia Gravis and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Myasthenia Gravis - The report reviews pipeline therapeutics for Myasthenia Gravis by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Myasthenia Gravis therapeutics and enlists all their major and minor projects - The report assesses Myasthenia Gravis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Myasthenia Gravis Reasons to Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Myasthenia Gravis - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Myasthenia Gravis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Myasthenia Gravis Overview 9 Therapeutics Development 10 Pipeline Products for Myasthenia Gravis - Overview 10 Pipeline Products for Myasthenia Gravis - Comparative Analysis 11 Myasthenia Gravis - Therapeutics under Development by Companies 12 Myasthenia Gravis - Therapeutics under Investigation by Universities/Institutes 14 Myasthenia Gravis - Pipeline Products Glance 15 Late Stage Products 15 Clinical Stage Products 16 Early Stage Products 17 Myasthenia Gravis - Products under Development by Companies 18 Myasthenia Gravis - Products under Investigation by Universities/Institutes 19 Myasthenia Gravis - Companies Involved in Therapeutics Development 20 Achillion Pharmaceuticals, Inc. 20 Akari Therapeutics, Plc 21 Alexion Pharmaceuticals, Inc. 22 arGEN-X BV 23 Baxalta Incorporated 24 Biokine Therapeutics Ltd. 25 BioMarin Pharmaceutical Inc. 26 CuraVac, Inc. 27 GlaxoSmithKline Plc 28 Grifols, S.A. 29 HanAll Biopharma Co., Ltd. 30 Karus Therapeutics Limited 31 Lead Discovery Center GmbH 32 Neurotune AG 33 Novartis AG 34 Pfizer Inc. 35 ReceptoPharm, Inc. 36 Regenesance BV 37 Toleranzia AB 38 Myasthenia Gravis - Therapeutics Assessment 39 Assessment by Monotherapy Products 39 Assessment by Target 40 Assessment by Mechanism of Action 42 Assessment by Route of Administration 44 Assessment by Molecule Type 46 Drug Profiles 48 amifampridine phosphate - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 ARGX-113 - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 BB-008 - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 belimumab - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 BKT-130 - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 CFZ-533 - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 Coversin - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 CVMG-01 - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 eculizumab - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 GL-2045 - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 HL-161 - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 immune globulin (human) - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 KA-1463 - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 Monoclonal Antibody to Inhibit C1q for Myasthenia Gravis - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 NT-1654 - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 Recombinant Protein for Myasthenia Gravis - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 regenemab - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 RPI-78M - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 SM-201 - Drug Profile 78 Product Description 78 Mechanism of Action 78 R&D Progress 78 Small Molecule to Inhibit Immunoproteasome Subunit LMP7 for Autoimmune Disorders and Viral Infections - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 Small Molecules to Inhibit Complement Factor D for Myasthenia Gravis - Drug Profile 80 Product Description 80 Mechanism of Action 80 R&D Progress 80 Vaccine for Myasthenia Gravis - Drug Profile 81 Product Description 81 Mechanism of Action 81 R&D Progress 81 Vaccine for Myasthenia Gravis - Drug Profile 82 Product Description 82 Mechanism of Action 82 R&D Progress 82 Myasthenia Gravis - Recent Pipeline Updates 83 Myasthenia Gravis - Dormant Projects 99 Myasthenia Gravis - Discontinued Products 100 Myasthenia Gravis - Product Development Milestones 101 Featured News & Press Releases 101 Feb 08, 2016: Catalyst Pharmaceuticals Announces Initiation of Investigator-Sponsored Study of Firdapse in Patients With MuSK-Antibody Positive Myasthenia Gravis 101 Dec 09, 2015: Nutra Pharma Announces Additional Orphan Drug Application for RPI-78M for the Treatment of Myasthenia Gravis 101 May 29, 2015: Double recognition of Toleranzia 102 Feb 26, 2015: Toleranzias Receives Orphan Drug Designation For Myasthenia Gravis 103 Dec 10, 2014: Soliris (eculizumab) Granted Orphan Drug Designation in Japan for the Treatment of Patients with Myasthenia Gravis 103 Aug 01, 2014: European Commission Grants Orphan Drug Designation to Soliris (eculizumab) for the Treatment of Patients with Myasthenia Gravis (MG) 104 Jun 17, 2014: FDA Grants Orphan Drug Designation to Soliris (eculizumab) for the Treatment of Patients with Myasthenia Gravis 104 Apr 24, 2014: Alexion Initiates Multinational Registration Trials of Eculizumab as a Potential Treatment for Patients with Relapsing Neuromyelitis Optica and Refractory Generalized Myasthenia Gravis 105 Apr 24, 2014: Toleranzia supported by VINNOVA 106 Apr 24, 2013: arGEN-X Advances ARGX-113 Into Preclinical Development For Autoimmune Disorders 106 Appendix 108 Methodology 108 Coverage 108 Secondary Research 108 Primary Research 108 Expert Panel Validation 108 Contact Us 108 Disclaimer 109
List of Tables Number of Products under Development for Myasthenia Gravis, H1 2016 10 Number of Products under Development for Myasthenia Gravis - Comparative Analysis, H1 2016 11 Number of Products under Development by Companies, H1 2016 13 Number of Products under Investigation by Universities/Institutes, H1 2016 14 Comparative Analysis by Late Stage Development, H1 2016 15 Comparative Analysis by Clinical Stage Development, H1 2016 16 Comparative Analysis by Early Stage Development, H1 2016 17 Products under Development by Companies, H1 2016 18 Products under Investigation by Universities/Institutes, H1 2016 19 Myasthenia Gravis - Pipeline by Achillion Pharmaceuticals, Inc., H1 2016 20 Myasthenia Gravis - Pipeline by Akari Therapeutics, Plc, H1 2016 21 Myasthenia Gravis - Pipeline by Alexion Pharmaceuticals, Inc., H1 2016 22 Myasthenia Gravis - Pipeline by arGEN-X BV, H1 2016 23 Myasthenia Gravis - Pipeline by Baxalta Incorporated, H1 2016 24 Myasthenia Gravis - Pipeline by Biokine Therapeutics Ltd., H1 2016 25 Myasthenia Gravis - Pipeline by BioMarin Pharmaceutical Inc., H1 2016 26 Myasthenia Gravis - Pipeline by CuraVac, Inc., H1 2016 27 Myasthenia Gravis - Pipeline by GlaxoSmithKline Plc, H1 2016 28 Myasthenia Gravis - Pipeline by Grifols, S.A., H1 2016 29 Myasthenia Gravis - Pipeline by HanAll Biopharma Co., Ltd., H1 2016 30 Myasthenia Gravis - Pipeline by Karus Therapeutics Limited, H1 2016 31 Myasthenia Gravis - Pipeline by Lead Discovery Center GmbH, H1 2016 32 Myasthenia Gravis - Pipeline by Neurotune AG, H1 2016 33 Myasthenia Gravis - Pipeline by Novartis AG, H1 2016 34 Myasthenia Gravis - Pipeline by Pfizer Inc., H1 2016 35 Myasthenia Gravis - Pipeline by ReceptoPharm, Inc., H1 2016 36 Myasthenia Gravis - Pipeline by Regenesance BV, H1 2016 37 Myasthenia Gravis - Pipeline by Toleranzia AB, H1 2016 38 Assessment by Monotherapy Products, H1 2016 39 Number of Products by Stage and Target, H1 2016 41 Number of Products by Stage and Mechanism of Action, H1 2016 43 Number of Products by Stage and Route of Administration, H1 2016 45 Number of Products by Stage and Molecule Type, H1 2016 47 Myasthenia Gravis Therapeutics - Recent Pipeline Updates, H1 2016 83 Myasthenia Gravis - Dormant Projects, H1 2016 99 Myasthenia Gravis - Discontinued Products, H1 2016 100
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
